0RQE Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Idorsia Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.77 |
| 52 Week High | CHF 3.69 |
| 52 Week Low | CHF 0.69 |
| Beta | 1.29 |
| 11 Month Change | -32.83% |
| 3 Month Change | -65.95% |
| 1 Year Change | -52.93% |
| 33 Year Change | -95.25% |
| 5 Year Change | -97.10% |
| Change since IPO | -93.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RQE | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -10.2% | -5.2% | 0.8% |
| 1Y | -52.9% | -20.1% | 6.6% |
Return vs Industry: 0RQE underperformed the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0RQE underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0RQE volatility | |
|---|---|
| 0RQE Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RQE's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RQE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.idorsia.com |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.
Idorsia Ltd Fundamentals Summary
| 0RQE fundamental statistics | |
|---|---|
| Market cap | CHF 142.00m |
| Earnings (TTM) | -CHF 296.43m |
| Revenue (TTM) | CHF 74.12m |
2.0x
P/S Ratio-0.5x
P/E RatioIs 0RQE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RQE income statement (TTM) | |
|---|---|
| Revenue | CHF 74.12m |
| Cost of Revenue | CHF 186.54m |
| Gross Profit | -CHF 112.41m |
| Other Expenses | CHF 184.01m |
| Earnings | -CHF 296.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -1.57 |
| Gross Margin | -151.66% |
| Net Profit Margin | -399.92% |
| Debt/Equity Ratio | -100.5% |
How did 0RQE perform over the long term?
See historical performance and comparison